Florent joined Earlybird Health as a Partner in 2020, bringing 28 years of expertise in investment and intellectual property management in the biopharma space. With a background in biotechnology, patent and private law, and a Kauffman Fellowship, he spent 15 years at the Novartis Venture Fund, where he seeded, invested in, and managed numerous startups. Florent has also founded three biotech companies, including Handl Therapeutics, which was sold in 2020. He led the financing for Oculis, an Earlybird Health I portfolio company, as a co-investor through the Novartis Venture Fund, and he is the co-founder and CEO of Priothera, another Earlybird Health I portfolio company.